Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate vs Calcium carbonate in hyperphosphatemia
NCT01514851Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2006
- Primary completion
- May 2006
- Countries
- 1
- Sponsor
- Bayer
- Modality
- Small Molecules
- Drugs
- lanthanum carbonate
- Conditions
- hyperphosphatemia
01
Overview
Phase 3, randomised, double-blind trial of lanthanum carbonate in hyperphosphatemia, sponsored by Bayer. Primary endpoint: Pre-dialysis serum phosphate at 8 weeks. Started Jan 2006; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with hyperphosphatemia (serum phosphate 5.6-11.0 mg/dL) undergoing hemodialysis for at least 3 months, excluding those with significant GI, liver, or cardiovascular diseases.
04
Endpoints
Primary
Pre-dialysis serum phosphate
Beyond the preview
Go deeper on NCT01514851.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514851.